Marta Fortuny
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404].
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 03, 2026
Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: December 12, 2025
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).
Journal: Alimentary pharmacology & therapeutics
Published: December 08, 2025
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
Journal: Hepatology (Baltimore, Md.)
Published: September 02, 2025
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
Journal: JHEP reports : innovation in hepatology
Published: July 04, 2025
Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.].
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 18, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 22, 2025
Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis.
Journal: Cancers
Published: April 29, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Journal: Nature
Published: March 01, 2024
Systemic therapies in hepatocellular carcinoma: A revolution?
Journal: United European gastroenterology journal
Published: September 03, 2023
Last Updated: 09/26/2026